While the largecap NIFTY 50 fell, midcaps extended their gains. Financials were the key drag on NIFTY as all the heavyweight ...

The company credited its performance to festive buying, particularly during Akshaya Tritiya, and steady wedding season sales.

The molecule, developed by its biotech division Sathgen Therapeutics, is currently undergoing Phase 1a clinical trials.

The company has fixed the price band at ₹387 to ₹407 per share, allowing bids in multiples of 36 equity shares.

The latest data release from RBI indicates that for the first time in 2025 forex reserves crossed USD 700 bn. Despite a fall ...

IndusInd Bank Limited posted a 3.9% decline in net advances to ₹3,34,477 Crore for the quarter ended June 30, 2025. In the ...

As per CCI’s order dated May 26, 2025, India Cements is directed to present financial statements for FY15-FY19.

The company currently operates with a solar PV module production capacity of 7.80 GW and a solar cell manufacturing capacity of 2.94 GW.

One of the fund categories that is attracting a lot of attention from institutions and HNIs is arbitrage funds. Any arbitrage funds typically buys in equity and sells in stock futures. Here are the ...

With the upgrade system, Southern Railway could meet its 3,000 MT loading target, announced the company in its filing with the bourses.